Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Category: Publications
Home
Publications
13
Oct
2023
Real-world (RW) characterization and frequency of
TSC1
and/or
TSC2
alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
0
0
October 13, 2023
Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
October 13, 2023
12
Oct
2023
Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines
0
0
October 12, 2023
Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines
October 12, 2023
05
Oct
2023
Phase 2 Study of nab-Sirolimus in Patients with Well-differentiated and Advanced or Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract, Lung, or Pancreas
0
2
October 5, 2023
October 5, 2023
05
Oct
2023
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
0
0
October 5, 2023
October 5, 2023
02
Jun
2023
Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
or
TSC2
Genes (PRECISION 1)
0
0
June 2, 2023
Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)
June 2, 2023
19
Apr
2023
Biomarker Analysis From AMPECT Correlating Response to
nab
-Sirolimus in PEComa With
TSC1
and
TSC2
Inactivating Alterations
0
2
April 19, 2023
April 19, 2023
18
Apr
2023
Synergistic Antitumor Activity of
nab
-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts
0
1
April 18, 2023
April 18, 2023
17
Apr
2023
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Patients With Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
0
0
April 17, 2023
April 17, 2023
26
Mar
2023
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
0
0
March 26, 2023
March 26, 2023
26
Mar
2023
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
0
0
March 26, 2023
March 26, 2023
Previous
1
2
3
4
5
6
Next
